LifeMD (LFMD)

LifeMD, Inc. (formerly Conversion Labs) is a leading telehealth company that is transforming the healthcare landscape with direct-to-patient product and service offerings. LifeMD's telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate, prescription medications and over-the-counter products delivered directly to the patient's home.

Company profile

Ticker

LFMD, LFMDP

Exchange

NASDAQ

Website

lifemd.com

CEO

Justin Schreiber

Incorporated

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Services - Offices & Clinics of Doctors of Medicine

Concord Medical Services • 1life Healthcare • Airsculpt • Teladoc Health • Oncology Institute Inc • Medico International • Hims & Hers Health • HealthLynked • Healthcare Solutions Management • Cano Health ...

Former names

CONVERSION LABS, INC., Immudyne, Inc.

SEC CIK

0000948320

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

WorkSimpli Software, LLC • Conversion Labs PR LLC ...

LFMD stock data

1M 1Y 5Y

News

From Benzinga Pro

LifeMD: Q2 Earnings Insights

11 Aug 22

LifeMD (NASDAQ:LFMD) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

CORRECTION: LifeMD Q2 Adj. EPS $(0.22) Beats $(0.35) Estimate, Sales $30.46M Miss $31.96M Estimate

11 Aug 22

LifeMD (NASDAQ:LFMD) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.35) by 37.14 percent. This is a 56.86 percent increase over losses of $(0.51) per share from the same

Earnings Scheduled For August 11, 2022

11 Aug 22

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

LifeMD's Earnings Outlook

10 Aug 22

LifeMD Announces Continued And Rapid Expansion Of Virtual Primary Care To Over 200 Conditions

19 Jul 22

Press releases

From Benzinga Pro

LifeMD, Inc. Reports Second Quarter 2022 Results

11 Aug 22

Record second quarter 2022 consolidated revenue of $30.5 million up 37% from the same year ago period.Adjusted EPS of $(0.22), 52% improvement versus the prior year, 12% sequentially.Remain on track to deliver

LifeMD, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 11, 2022

27 Jul 22

NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a rapidly growing direct-to-patient telehealth company, today announced that it will report its financial results for the second quarter ended

LifeMD Announces Continued and Rapid Expansion of Virtual Primary Care To over 200 Conditions

19 Jul 22

NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD, a leading direct-to-patient telehealth company, today announced the continued and rapid expansion of its Virtual Primary Care platform. Since its

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

27 Jun 22

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

11 Aug 22

20 Aug 22

31 Dec 22

Financial summary

Financial statements Chart LFMD financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	11.72M	11.72M	11.72M	11.72M	11.72M	11.72M
Cash burn (monthly)	4.46M	474.74K	5.21M	5.1M	3.37M	2.62M
Cash used (since last report)	7.51M	800.27K	8.79M	8.59M	5.67M	4.42M
Cash remaining	4.21M	10.92M	2.93M	3.13M	6.04M	7.3M
Runway (months of cash)	0.9	23.0	0.6	0.6	1.8	2.8

Beta Read what these cash burn values mean

Financial data from LifeMD earnings reports.

Recent insider trades

LFMD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 May 22	Naveen Bhatia	Common Stock	Buy	Acquire P	No	No	2.136	50,000	106.8K	246,349
14 Mar 22	Eric Harold Yecies	Common Stock	Buy	Acquire P	No	No	3.14	5,000	15.7K	51,000
10 Mar 22	Joseph DiTrolio	Common Stock, par value $0.01	Buy	Acquire P	No	No	3.28	2,000	6.56K	24,500
11 Feb 22	Schreiber Justin	Common Stock	Gift	Dispose G	Yes	No	0	60,000	0	2,794,620
11 Feb 22	Nicholas P Alvarez	Common Stock	Gift	Acquire G	No	No	0	60,000	0	169,288

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

LFMD institutional ownership history Ownership history

26.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	46	53	-13.2%
Opened positions	3	8	-62.5%
Closed positions	10	27	-63.0%
Increased positions	14	12	+16.7%
Reduced positions	14	22	-36.4%

13F shares	Current	Prev Q	Change
Total value	31.57M	34.99M	-9.8%
Total shares	8.09M	8.77M	-7.7%
Total puts	80.5K	144.8K	-44.4%
Total calls	77.1K	152.8K	-49.5%
Total put/call ratio	1.0	0.9	+10.2%

Largest owners	Shares	Value	Change
Stefan Galluppi	1.65M	$0	0.0%
Integrated Core Strategies	1.27M	$12.35M	0.0%
RILY B. Riley Financial	1.2M	$4.24M	+5.2%
Vanguard	809.94K	$2.86M	-10.1%
BLK Blackrock	425.62K	$1.5M	+0.5%
AFG American Financial	340K	$1.2M	0.0%
Granahan Investment Management	295.75K	$1.04M	+448.1%
Two Sigma Advisers	271.9K	$960K	-45.4%
Geode Capital Management	189.45K	$668K	+2.8%
Barry Investment Advisors	178.47K	$630K	0.0%

Largest transactions	Shares	Bought/sold	Change
Granahan Investment Management	295.75K	+241.79K	+448.1%
Two Sigma Advisers	271.9K	-226.1K	-45.4%
Two Sigma Investments	150.78K	-216.64K	-59.0%
Renaissance Technologies	0	-184.11K	EXIT
Gsa Capital Partners	146.96K	+146.96K	NEW
Marshall Wace	0	-128.12K	EXIT
Vanguard	809.94K	-90.64K	-10.1%
D. E. Shaw & Co.	12.78K	-88.89K	-87.4%
Millennium Management	0	-88.58K	EXIT
Sontag Advisory	62.5K	+62.5K	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

GoodRx

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: amenable, assumption, Counsel, decline, doubt, Eric, forward, frequently, fuel, GC, hurt, inflation, lose, meantime, mediate, mediation, moving, prejudice, rendered, stay, uncertainty

Removed: achieve, assist, assure, Axle, blood, burn, conclusion, continuing, curtail, CVLBPR, enable, establishing, exceeded, expanding, facilitate, furnish, grouped, improvement, ineligible, install, largely, lead, level, lowest, met, MP, nontransferable, nursing, practice, provision, qualify, revocable, scheduling, sum, therewith

From filing 10-Q 2022 Q2

Financial reports

View all